nach oben

American Journal of Clinical Dermatology

Erschienen in:

18.01.2021 | Review Article

HLA-Cw1 and Psoriasis

verfasst von: Yi-Wei Huang, Tsen-Fang Tsai

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Psoriasis is a chronic inflammatory skin condition with regional and ethnic differences in its prevalence and clinical manifestations. Human leukocyte antigen (HLA)-Cw6 is the disease allele conferring the greatest risk to psoriasis, but its prevalence is lower in Asian individuals. Recent studies have found associations between HLA-Cw1 and some Asian populations with psoriasis, especially Southern Chinese. HLA-Cw6 was associated with type I early-onset psoriasis, guttate psoriasis, Koebner phenomenon, and better response to methotrexate, interleukin (IL)-12/23, IL-17, and IL-23 targeting drugs. In contrast, HLA-Cw1 positivity has been associated with erythrodermic psoriasis, pustular psoriasis, and the axial type of psoriatic arthritis. Furthermore, HLA-Cw1 was more frequently associated with high-need patients who did not respond to conventional therapies. No known trigger factor nor autoantigen has been identified for HLA-Cw1 positivity. However, HLA-Cw1 has been linked to some viral agents. For example, cytotoxic T lymphocytes recognize multiple cytomegalovirus pp65-derived epitopes presented by HLA alleles, including HLA-C*01:02. In addition, cytomegalovirus can lead to severe exacerbation of psoriatic skin disease. The proposed interaction between viral infection, HLA-Cw1, and psoriasis is through the killer cell immunoglobulin-like receptors of natural killer cells. Given the diverse nature of psoriasis pathogenesis and the difference in HLA-Cw prevalence in different racial groups, more studies are needed to confirm the role of HLA-Cw1 in psoriasis.

Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12. https://doi.org/10.1111/jdv.13854.CrossRefPubMed

Singh S, Pradhan D, Puri P, Ramesh V, Aggarwal S, Nayek A, et al. Genomic alterations driving psoriasis pathogenesis. Gene. 2019;683:61–71. https://doi.org/10.1016/j.gene.2018.09.042.CrossRefPubMed

Capon F. The genetic basis of psoriasis. Int J Mol Sci. 2017;18(12):2526. https://doi.org/10.3390/ijms18122526.CrossRefPubMedCentral

Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, et al. Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat Commun. 2017;8:15382. https://doi.org/10.1038/ncomms15382.CrossRefPubMedPubMedCentral

Prinz JC. Autoimmune aspects of psoriasis: heritability and autoantigens. Autoimmun Rev. 2017;16(9):970–9. https://doi.org/10.1016/j.autrev.2017.07.011.CrossRefPubMed

Zipeto D, Beretta A. HLA-C and HIV-1: friends or foes? Retrovirology. 2012;9:39. https://doi.org/10.1186/1742-4690-9-39.CrossRefPubMedPubMedCentral

Chen L, Tsai T-F. HLA-Cw6 and psoriasis. Br J Dermatol. 2018;178(4):854–62. https://doi.org/10.1111/bjd.16083.CrossRefPubMed

Chang YT, Tsai SF, Lee DD, Shiao YM, Huang CY, Liu HN, et al. A study of candidate genes for psoriasis near HLA-C in Chinese patients with psoriasis. Br J Dermatol. 2003;148(3):418–23. https://doi.org/10.1046/j.1365-2133.2003.05166.x.CrossRefPubMed

Tsai TF, Hu CY, Tsai WL, Chu CY, Lin SJ, Liaw SH, et al. HLA-Cw6 specificity and polymorphic residues are associated with susceptibility among Chinese psoriatics in Taiwan. Arch Dermatol Res. 2002;294(5):214–20. https://doi.org/10.1007/s00403-002-0324-0.CrossRefPubMed

10.

Tiilikainen A, Lassus A, Karvonen J, Vartiainen P, Julin M. Psoriasis and HLA-Cw6. Br J Dermatol. 1980;102(2):179–84. https://doi.org/10.1111/j.1365-2133.1980.tb05690.x.CrossRefPubMed

11.

Cai M, Huang H, Ran D, Zheng X, Wen L, Zhu Z, et al. HLA-C*01:02 and HLA-A*02:07 confer risk specific for psoriatic patients in Southern China. J Invest Dermatol. 2019;139(9):2045-8.e4. https://doi.org/10.1016/j.jid.2019.02.027.CrossRefPubMed

12.

Stuart PE, Nair RP, Hiremagalore R, Kullavanijaya P, Kullavanijaya P, Tejasvi T, et al. Comparison of MHC class I risk haplotypes in Thai and Caucasian psoriatics shows locus heterogeneity at PSORS1. Tissue Antigens. 2010;76(5):387–97. https://doi.org/10.1111/j.1399-0039.2010.01526.x.CrossRefPubMedPubMedCentral

13.

Choonhakarn C, Romphruk A, Puapairoj C, Jirarattanapochai K, Romphruk A, Leelayuwat C. Haplotype associations of the major histocompatibility complex with psoriasis in Northeastern Thais. Int J Dermatol. 2002;41(6):330–4. https://doi.org/10.1046/j.1365-4362.2002.01496.x.CrossRefPubMed

14.

Onsun N, Pirmit S, Ozkaya D, Çelik Ş, Rezvani A, Cengiz FP, et al. The HLA-Cw12 allele is an important susceptibility allele for psoriasis and is associated with resistant psoriasis in the Turkish population. Sci World J. 2019;2019:7848314. https://doi.org/10.1155/2019/7848314.CrossRef

15.

Nanda A, Al-Fouzan AS, El-Kashlan M, Al-Sweih N, Al-Muzairai I. Salient features and HLA markers of childhood psoriasis in Kuwait. Clin Exp Dermatol. 2000;25(2):147–51. https://doi.org/10.1046/j.1365-2230.2000.00598.x.CrossRefPubMed

16.

Shaiq PA, Stuart PE, Latif A, Schmotzer C, Kazmi AH, Khan MS, et al. Genetic associations of psoriasis in a Pakistani population. Br J Dermatol. 2013;169(2):406–11. https://doi.org/10.1111/bjd.12313.CrossRefPubMedPubMedCentral

17.

Shen M, Lim SWD, Tan ES, Oon HH, Ren EC. HLA correlations with clinical phenotypes and risk of metabolic comorbidities in Singapore Chinese psoriasis patients. Mol Diagn Ther. 2019;23(6):751–60. https://doi.org/10.1007/s40291-019-00423-z.CrossRefPubMed

18.

Yan D, Afifi L, Jeon C, Cordoro KM, Liao W. A cross-sectional study of psoriasis triggers among different ethno-racial groups. J Am Acad Dermatol. 2017;77(4):756-8.e1. https://doi.org/10.1016/j.jaad.2017.04.1109.CrossRefPubMedPubMedCentral

19.

Chan TC, Sanyal RD, Pavel AB, Glickman J, Zheng X, Xu H, et al. Atopic dermatitis in Chinese patients shows T(H)2/T(H)17 skewing with psoriasiform features. J Allergy Clin Immunol. 2018;142(3):1013–7. https://doi.org/10.1016/j.jaci.2018.06.016.CrossRefPubMed

20.

Chen J, Li C, Li H, Yu H, Zhang X, Yan M, et al. Identification of a T(H) 2-high psoriasis cluster based on skin biomarker analysis in a Chinese psoriasis population. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16563.CrossRefPubMedPubMedCentral

21.

Lo Y, Chiu HY, Tsai TF. Clinical features and genetic polymorphism in Chinese patients with erythrodermic psoriasis in a single dermatologic clinic. Mol Diagn Ther. 2019;24(1):85–93. https://doi.org/10.1007/s40291-019-00441-x.CrossRef

22.

Ozawa A, Miyahara M, Sugai J, Iizuka M, Kawakubo Y, Matsuo I, et al. HLA class I and II alleles and susceptibility to generalized pustular psoriasis: significant associations with HLA-Cw1 and HLA-DQB1*0303. J Dermatol. 1998;25(9):573–81. https://doi.org/10.1111/j.1346-8138.1998.tb02461.x.CrossRefPubMed

23.

Romaní de Gabriel J. Darwinian medicine and psoriasis. Actas Dermosifiliogr. 2015;106(3):189–94. https://doi.org/10.1016/j.ad.2014.06.009.

24.

Méndez-Samperio P. The human cathelicidin hCAP18/LL-37: a multifunctional peptide involved in mycobacterial infections. Peptides. 2010;31(9):1791–8. https://doi.org/10.1016/j.peptides.2010.06.016.CrossRefPubMed

25.

Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang Y-H, Homey B, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564–9. https://doi.org/10.1038/nature06116.CrossRefPubMed

26.

Mabuchi T, Hirayama N. Binding affinity and interaction of LL-37 with HLA-C*06:02 in psoriasis. J Invest Dermatol. 2016;136(9):1901–3. https://doi.org/10.1016/j.jid.2016.04.033.CrossRefPubMed

27.

Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, Olafsson JH, Petersen H, Sigurdsson MI, et al. HLA-Cw6 homozygosity in plaque psoriasis is associated with streptococcal throat infections and pronounced improvement after tonsillectomy: a prospective case series. J Am Acad Dermatol. 2016;75(5):889–96. https://doi.org/10.1016/j.jaad.2016.06.061.CrossRefPubMedPubMedCentral

28.

Arakawa A, Siewert K, Stöhr J, Besgen P, Kim SM, Rühl G, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med. 2015;212(13):2203–12. https://doi.org/10.1084/jem.20151093.CrossRefPubMedPubMedCentral

29.

Yunusbaeva M, Valiev R, Bilalov F, Sultanova Z, Sharipova L, Yunusbayev B. Psoriasis patients demonstrate HLA-Cw*06:02 allele dosage-dependent T cell proliferation when treated with hair follicle-derived keratin 17 protein. Sci Rep. 2018;8(1):6098. https://doi.org/10.1038/s41598-018-24491-z.CrossRefPubMedPubMedCentral

30.

Johnston A, Gudjonsson JE, Sigmundsdottir H, Love TJ, Valdimarsson H. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin Exp Immunol. 2004;138(1):83–93. https://doi.org/10.1111/j.1365-2249.2004.00600.x.CrossRefPubMedPubMedCentral

31.

Haapasalo K, Koskinen LLE, Suvilehto J, Jousilahti P, Wolin A, Suomela S, et al. The psoriasis risk allele HLA-C*06:02 shows evidence of association with chronic or recurrent streptococcal tonsillitis. Infect Immun. 2018;86(10):e00304-e318. https://doi.org/10.1128/iai.00304-18.CrossRefPubMedPubMedCentral

32.

Mallbris L, Wolk K, Sánchez F, Ståhle M. HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study. BMC Dermatol. 2009;9(1):5. https://doi.org/10.1186/1471-5945-9-5.CrossRefPubMedPubMedCentral

33.

Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol. 1998;161(2):571.PubMed

34.

Moretta A, Vitale M, Bottino C, Orengo AM, Morelli L, Augugliaro R, et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells: anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med. 1993;178(2):597–604. https://doi.org/10.1084/jem.178.2.597.CrossRefPubMed

35.

Fadda L, Borhis G, Ahmed P, Cheent K, Pageon SV, Cazaly A, et al. Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci U S A. 2010;107(22):10160–5. https://doi.org/10.1073/pnas.0913745107.CrossRefPubMedPubMedCentral

36.

Enciso-Vargas M, Alvarado-Ruíz L, Suárez-Villanueva AS, Macías-Barragán J, Montoya-Buelna M, Oceguera-Contreras E, et al. Association study between psoriatic arthritis and killer immunoglobulin-like receptor (KIR) genes: a meta-analysis. Immunol Invest. 2020;2020:1–12. https://doi.org/10.1080/08820139.2020.1713145.CrossRef

37.

Yan D, Afifi L, Jeon C, Cordoro KM, Liao W. A cross-sectional study of the distribution of psoriasis subtypes in different ethno-racial groups. Dermatol Online J. 2018;24(7):13030.PubMed

38.

Güssow D, Rein RS, Meijer I, de Hoog W, Seemann GH, Hochstenbach FM, et al. Isolation, expression, and the primary structure of HLA-Cw1 and HLA-Cw2 genes: evolutionary aspects. Immunogenetics. 1987;25(5):313–22. https://doi.org/10.1007/bf00404424.CrossRefPubMed

39.

Shen Y, Cao D, Li Y, Kulski JK, Shi L, Jiang H, et al. Distribution of HLA-A, -B, and -C alleles and HLA/KIR combinations in Han population in China. J Immunol Res. 2014;2014:565296. https://doi.org/10.1155/2014/565296.CrossRefPubMedPubMedCentral

40.

Chen N, Wang W, Wang F, Dong L, Zhao S, Zhang W, et al. The distributions of HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 allele and haplotype at high-resolution level in Zhejiang Han population of China. Int J Immunogenet. 2019;46(1):7–16. https://doi.org/10.1111/iji.12411.CrossRefPubMed

41.

Pavlos R, McKinnon EJ, Ostrov DA, Peters B, Buus S, Koelle D, et al. Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. Sci Rep. 2017;7(1):8653. https://doi.org/10.1038/s41598-017-08876-0.CrossRefPubMedPubMedCentral

42.

Andersen MH, Søndergaard I, Zeuthen J, Elliott T, Haurum JS. An assay for peptide binding to HLA-Cw*0102. Tissue Antigens. 1999;54(2):185–90. https://doi.org/10.1034/j.1399-0039.1999.540210.x.CrossRefPubMed

43.

Hirata J, Hirota T, Ozeki T, Kanai M, Sudo T, Tanaka T, et al. Variants at HLA-A, HLA-C, and HLA-DQB1 confer risk of psoriasis vulgaris in Japanese. J Invest Dermatol. 2018;138(3):542–8. https://doi.org/10.1016/j.jid.2017.10.001.CrossRefPubMed

44.

West J, Ogston S, Berg J, Palmer C, Fleming C, Kumar V, et al. HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment. Clin Exp Dermatol. 2017;42(6):651–5. https://doi.org/10.1111/ced.13100.CrossRefPubMed

45.

Indhumathi S, Rajappa M, Chandrashekar L, Ananthanarayanan PH, Thappa DM, Negi VS. Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis. Eur J Clin Pharmacol. 2017;73(8):965–71. https://doi.org/10.1007/s00228-017-2255-x.CrossRefPubMed

46.

Chiu HY, Wang TS, Chan CC, Cheng YP, Lin SJ, Tsai TF. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis. Br J Dermatol. 2014;171(5):1181–8. https://doi.org/10.1111/bjd.13056.CrossRefPubMed

47.

van Vugt LJ, van den Reek J, Hannink G, Coenen MJH, de Jong E. Association of HLA-C*06:02 status with differential response to ustekinumab in patients with psoriasis: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(6):708–15. https://doi.org/10.1001/jamadermatol.2019.0098.CrossRefPubMedPubMedCentral

48.

Burlando M, Russo R, Clapasson A, Carmisciano L, Stecca A, Cozzani E, et al. The HLA-Cw6 dilemma: is it really an outcome predictor in psoriasis patients under biologic therapy? A monocentric retrospective analysis. J Clin Med. 2020;9(10):3140. https://doi.org/10.3390/jcm9103140.CrossRefPubMedCentral

49.

Morelli M, Galluzzo M, Madonna S, Scarponi C, Scaglione GL, Galluccio T, et al. HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. Expert Opin Biol Ther. 2020. https://doi.org/10.1080/14712598.2021.1862082.CrossRefPubMed

50.

Liu X, DePrimo S, Chen Y, Li S, Munoz-Elias E. Association between HLA-Cw6 status and response to guselkumab in patients with moderate to severe plaque psoriasis. J Invest Dermatol. 2018;138(5 Suppl.):S76. https://doi.org/10.1016/j.jid.2018.03.458.CrossRef

51.

Costanzo A, Bianchi L, Flori ML, Malara G, Stingeni L, Bartezaghi M, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol. 2018;179(5):1072–80. https://doi.org/10.1111/bjd.16705.CrossRefPubMed

52.

Abrouk M, Lee K, Brodsky M, Nakamura M, Singh R, Zhu TH, et al. Ethnicity affects the presenting severity of psoriasis. J Am Acad Dermatol. 2017;77(1):180–2. https://doi.org/10.1016/j.jaad.2017.02.042.CrossRefPubMed

53.

Romphruk AV, Romphruk A, Choonhakarn C, Puapairoj C, Inoko H, Leelayuwat C. Major histocompatibility complex class I chain-related gene A in Thai psoriasis patients: MICA association as a part of human leukocyte antigen-B-Cw haplotypes. Tissue Antigens. 2004;63(6):547–54. https://doi.org/10.1111/j.0001-2815.2004.00238.x.CrossRefPubMed

54.

Chiu HY, Huang PY, Jee SH, Hu CY, Chou CT, Chang YT, et al. HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis. Br J Dermatol. 2012;166(2):288–97. https://doi.org/10.1111/j.1365-2133.2011.10688.x.CrossRefPubMed

55.

Kozin F, Duquesnoy R, Rodey GE, Lightfoot RW, Ryan LM. High prevalence of HLA-Cw1 and Cw2 antigens in spondylarthritis. Arthritis Rheum. 1978;21(8):889–95. https://doi.org/10.1002/art.1780210804.CrossRefPubMed

56.

Duquesnoy RJ, Kozin F, Rodey GE. High prevalence of HLA-B27, Cw1 and Cw2 in patients with seronegative spondyloarthritis. Tissue Antigens. 1978;12(1):58–62.PubMed

57.

Säfwenberg J, Domeij-Nyberg B, Kjällman M. HLA antigens in females with ankylosing spondylitis and other forms of seronegative rheumatic diseases. Scand J Rheumatol. 1978;7(3):177–82. https://doi.org/10.3109/03009747809095650.CrossRefPubMed

58.

Arnett FC, Hochberg MC, Bias WB. HLA-C locus antigens in HLA-B27 associated arthritis. Arthritis Rheum. 1978;21(8):885–8. https://doi.org/10.1002/art.1780210803.CrossRefPubMed

59.

Gerber LH, Murray CL, Perlman SG, Barth WF, Decker JL, Nigra TA, et al. Human lymphocyte antigens characterizing psoriatic arthritis and its subtypes. J Rheumatol. 1982;9(5):703–7.PubMed

60.

López-Larrea C, Torre Alonso JC, Rodriguez Perez A, Coto E. HLA antigens in psoriatic arthritis subtypes of a Spanish population. Ann Rheum Dis. 1990;49(5):318–9. https://doi.org/10.1136/ard.49.5.318.CrossRefPubMedPubMedCentral

61.

Sin CZ, Wang TS, Chiu HY, Tsai TF. Human leukocyte antigen and demographic characteristics in Chinese patients with active peripheral type psoriatic arthritis who had inadequate response to conventional disease-modifying antirheumatic drugs in a single dermatologic clinic. PLoS ONE. 2019;14(1):e0210076. https://doi.org/10.1371/journal.pone.0210076.CrossRefPubMedPubMedCentral

62.

Shao L-N, Wang N, Zhou S-H, Wang Z. Associations between human leukocyte antigen C locus polymorphism and psoriatic arthritis in populations of European and Middle Eastern descent: a meta-analysis. Ann Saudi Med. 2020;40(4):338–46. https://doi.org/10.5144/0256-4947.2020.338.CrossRefPubMedPubMedCentral

63.

Suo C, Xu H, Khor CC, Ong RT, Sim X, Chen J, et al. Natural positive selection and north-south genetic diversity in East Asia. Eur J Hum Genet. 2012;20(1):102–10. https://doi.org/10.1038/ejhg.2011.139.CrossRefPubMed

64.

Siegel RJ, Bridges SL Jr, Ahmed S. HLA-C: an accomplice in rheumatic diseases. ACR Open Rheumatol. 2019;1(9):571–9. https://doi.org/10.1002/acr2.11065.CrossRefPubMedPubMedCentral

65.

Correale P, Mutti L, Pentimalli F, Baglio G, Saladino RE, Sileri P, et al. HLA-B*44 and C*01 prevalence correlates with Covid19 spreading across Italy. Int J Mol Sci. 2020;21(15):5205. https://doi.org/10.3390/ijms21155205.CrossRefPubMedCentral

66.

Balamurugan A, Sharma SK, Mehra NK. Human leukocyte antigen class I supertypes influence susceptibility and severity of tuberculosis. J Infect Dis. 2004;189(5):805–11. https://doi.org/10.1086/381689.CrossRefPubMed

67.

Jakubowiak WM, Bogorodskaya EM, Borisov SE, Danilova ID, Kourbatova EV. Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions. Int J Tuberc Lung Dis. 2007;11(1):46–53.PubMed

68.

Liu Y, Zhao Z, Li T, Liao Q, Kushner N, Touzjian NY, et al. High resolution human leukocyte antigen class I allele frequencies and HIV-1 infection associations in Chinese Han and Uyghur cohorts. PLoS ONE. 2012;7(12):e50656. https://doi.org/10.1371/journal.pone.0050656.CrossRefPubMedPubMedCentral

69.

Fadda L, Körner C, Kumar S, van Teijlingen NH, Piechocka-Trocha A, Carrington M, et al. HLA-Cw*0102-restricted HIV-1 p24 epitope variants can modulate the binding of the inhibitory KIR2DL2 receptor and primary NK cell function. PLoS Pathog. 2012;8(7):e1002805. https://doi.org/10.1371/journal.ppat.1002805.CrossRefPubMedPubMedCentral

70.

de Sá NBR, Ribeiro-Alves M, da Silva TP, Pilotto JH, Rolla VC, Giacoia-Gripp CBW, et al. Clinical and genetic markers associated with tuberculosis, HIV-1 infection, and TB/HIV-immune reconstitution inflammatory syndrome outcomes. BMC Infect Dis. 2020;20(1):59. https://doi.org/10.1186/s12879-020-4786-5.CrossRefPubMedPubMedCentral

71.

Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol. 2011;89(2):216–24. https://doi.org/10.1038/icb.2010.78.CrossRefPubMed

72.

Ceccarelli M, Venanzi Rullo E, Vaccaro M, Facciolà A, d’Aleo F, Paolucci IA, et al. HIV-associated psoriasis: epidemiology, pathogenesis, and management. Dermatol Ther. 2019;32(2):e12806. https://doi.org/10.1111/dth.12806.CrossRefPubMed

73.

Morar N, Willis-Owen SA, Maurer T, Bunker CB. HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect Dis. 2010;10(7):470–8. https://doi.org/10.1016/s1473-3099(10)70101-8.CrossRefPubMed

74.

Yen YF, Jen IA, Chen M, Lan YC, Lee CY, Chuang PH, et al. HIV infection increases the risk of incident psoriasis: a nationwide population-based cohort study in Taiwan. J Acquir Immune Defic Syndr. 2017;75(5):493–9. https://doi.org/10.1097/qai.0000000000001431.CrossRefPubMed

75.

Gambardella A, Licata G, Calabrese G, De Rosa A, Pagliuca F, Alfano R, et al. CMV infection: a clinical challenge in biological therapy? The case of asymptomatic patients with persistent positive immunoglobulin M anti-CMV treated with secukinumab. Psoriasis (Auckl). 2020;10:57–60. https://doi.org/10.2147/ptt.S284701.CrossRefPubMedPubMedCentral

76.

Weitz M, Kiessling C, Friedrich M, Prösch S, Höflich C, Kern F, et al. Persistent CMV infection correlates with disease activity and dominates the phenotype of peripheral CD8+ T cells in psoriasis. Exp Dermatol. 2011;20(7):561–7. https://doi.org/10.1111/j.1600-0625.2011.01250.x.CrossRefPubMed

77.

Kondo E, Akatsuka Y, Kuzushima K, Tsujimura K, Asakura S, Tajima K, et al. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood. 2004;103(2):630–8. https://doi.org/10.1182/blood-2003-03-0824.CrossRefPubMed

78.

Hyun SJ, Sohn HJ, Lee HJ, Lee SD, Kim S, Sohn DH, et al. Comprehensive analysis of cytomegalovirus pp65 antigen-specific CD8(+) T cell responses according to human leukocyte antigen class I allotypes and intraindividual dominance. Front Immunol. 2017;8:1591. https://doi.org/10.3389/fimmu.2017.01591.CrossRefPubMedPubMedCentral

79.

Chiu H-Y, Chan C-C, Tsai T-F. The impact of long-term secukinumab treatment on Epstein-Barr virus and cytomegalovirus loads in patients with psoriasis. Int J Dermatol. 2016;55(11):e600–2. https://doi.org/10.1111/ijd.13346.CrossRefPubMed

80.

Horibe H, Ueyama C, Fujimaki T, Oguri M, Kato K, Ichihara S, et al. Association of a polymorphism of BTN2A1 with dyslipidemia in community-dwelling individuals. Mol Med Rep. 2014;9(3):808–12. https://doi.org/10.3892/mmr.2014.1902.CrossRefPubMed

81.

Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(12):1417–23. https://doi.org/10.1001/jamadermatol.2018.3631.CrossRefPubMedPubMedCentral

82.

Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90(4):636–47. https://doi.org/10.1016/j.ajhg.2012.02.020.CrossRefPubMedPubMedCentral

83.

Jung ES, Cheon JH, Lee JH, Park SJ, Jang HW, Chung SH, et al. HLA-C*01 is a risk factor for Crohn’s disease. Inflamm Bowel Dis. 2016;22(4):796–806. https://doi.org/10.1097/mib.0000000000000693.CrossRefPubMed

84.

Ungprasert P, Wijarnpreecha K, Cheungpasitporn W. Patients with psoriasis have a higher risk of schizophrenia: a systematic review and meta-analysis of observational studies. J Postgrad Med. 2019;65(3):141–5. https://doi.org/10.4103/jpgm.JPGM_253_18.CrossRefPubMedPubMedCentral

85.

Ungprasert P, Wijarnpreecha K, Cheungpasitporn W. Patients with schizophrenia have a higher risk of psoriasis: a systematic review and meta-analysis. Psychiatry Res. 2018;259:422–6. https://doi.org/10.1016/j.psychres.2017.11.021.CrossRefPubMed

86.

Strange A, Riley BP, Spencer CCA, Morris DW, Pirinen M, O’Dushlaine CT, et al. Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia. Biol Psychiatry. 2012;72(8):620–8. https://doi.org/10.1016/j.biopsych.2012.05.035.CrossRef

87.

Pouget JG, Han B, Wu Y, Mignot E, Ollila HM, Barker J, et al. Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk. Hum Mol Genet. 2019;28(20):3498–513. https://doi.org/10.1093/hmg/ddz145.CrossRefPubMedPubMedCentral

88.

Cardili RN, Deghaide NS, Mendes-Junior CT, Donadi EA, Souza CS. HLA-C and TNF gene polymorphisms are associated with psoriasis in Brazilian patients. Int J Dermatol. 2016;55(1):e16-22. https://doi.org/10.1111/ijd.12894.CrossRefPubMed

89.

Cibulova A, Zajacova M, Fojtikova M, Stolfa J, Sedova L, Cejkova P, et al. The HLA-Cw*06 allele and −1149 G/T polymorphism of extrapituitary promoter of PRL gene as a possible common genetic predisposing factors to psoriasis vulgaris and psoriatic arthritis in Czech population. Rheumatol Int. 2013;33(4):913–9. https://doi.org/10.1007/s00296-012-2472-7.CrossRefPubMed

90.

Gonzalez S, Martinez-Borra J, Torre-Alonso JC, Gonzalez-Roces S, del Río SJ, Rodriguez-Pérez A, et al. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum. 1999;42(5):1010–6. doi: https://doi.org/10.1002/1529-0131(199905)42:5<1010::Aid-anr21>3.0.Co;2-h.

91.

Kim T-G, Han H, Lee HJ, Youn JI, Kim TY. The association of psoriasis with human leukocyte antigens in Korean population and the influence of age of onset and sex. J Invest Dermatol. 2000;114(2):309–13. https://doi.org/10.1046/j.1523-1747.2000.00863.x.CrossRefPubMed

92.

Nakagawa H, Asahina A, Akazaki S, Tokunaga K, Matsuki K, Ishibashi Y, et al. Association of Cw11 in Japanese patients with psoriasis vulgaris. Tissue Antigens. 1990;36(5):241–2. https://doi.org/10.1111/j.1399-0039.1990.tb01835.x.CrossRefPubMed

93.

Shawkatová I, Javor J, Párnická Z, Kozub P, Zilínková M, Frey P, et al. HLA-C, DRB1 and DQB1 alleles involved in genetic predisposition to psoriasis vulgaris in the Slovak population. Folia Microbiol (Praha). 2013;58(4):319–24. https://doi.org/10.1007/s12223-012-0213-7.CrossRefPubMed

94.

Szczerkowska Dobosz A, Rebała K, Szczerkowska Z, Nedoszytko B. HLA-C locus alleles distribution in patients from northern Poland with psoriatic arthritis: preliminary report. Int J Immunogenet. 2005;32(6):389–91. https://doi.org/10.1111/j.1744-313X.2005.00543.x.CrossRefPubMed

95.

Zhang XJ, Zhang AP, Yang S, Gao M, Wei SC, He PP, et al. Association of HLA class I alleles with psoriasis vulgaris in southeastern Chinese Hans. J Dermatol Sci. 2003;33(1):1–6. https://doi.org/10.1016/s0923-1811(03)00157-9.CrossRefPubMed

Titel: HLA-Cw1 and Psoriasis
verfasst von: Yi-Wei Huang
Tsen-Fang Tsai
Publikationsdatum: 18.01.2021
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 3/2021
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-020-00585-1

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Nahaufnahme Rosazea auf der Wange/© Alessandro Grandini / stock.adobe.com (Symbolbild mit Fotomodell), Eine Tätowierung wird mit roter Farbe ausgefüllt/© nagaets / stock.adobe.com (Symbolbild mit Fotomodell), Operation/© Peakstock / Stock.adobe.com (Symbolbild mit Fotomodellen), Rechte Aa. carotis interna mit Wandverdickung bei Riesenzellarteriitis/© Kisyova H et al. | all rights reserved Springer Medizin Verlag GmbH

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Erythema Nodosum: A Practical Approach and Diagnostic Algorithm

The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma

Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma

Management of Difficult-to-Treat Warts: Traditional and New Approaches

50 Years of Topical Retinoids for Acne: Evolution of Treatment